Key result
Assaying serum apolipoprotein B100 (apoB) is considered better than calculated non-HDL-C or LDL-C for guiding statin treatment, with higher concentrations noted in hypertriglyceridaemic patients.
The discussion highlights the potential superiority of apolipoprotein B over traditional lipid markers like LDL-C and non-HDL-C for guiding statin therapy.
The author discusses research on the assaying serum apolipoprotein B100 (apoB). He notes the study considering apoB better than the calculated non-high-density lipoprotein (non-HDL-C) or low-density lipoprotein cholesterol (LDL-C) for statin treatment. He points out the results of another research revealing the higher concentrations of serum apoB in hypertriglyceridaemic patients than from LDL-C concentration. He adds that these concentrations are high in familial defective apoB (FDB).
No takes yet. Share an insight, caveat, or question.
Martin Crook (2011) conducted an editorial in Hypertriglyceridaemia and familial defective apoB. Assaying serum apolipoprotein B100 (apoB) vs. Calculated non-HDL-C or LDL-C was evaluated. Assaying serum apolipoprotein B100 (apoB) is considered better than calculated non-HDL-C or LDL-C for guiding statin treatment, with higher concentrations noted in hypertriglyceridaemic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: